DENTALI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 25.096
EU - Europa 13.118
AS - Asia 3.338
Continente sconosciuto - Info sul continente non disponibili 33
SA - Sud America 29
OC - Oceania 8
AF - Africa 5
Totale 41.627
Nazione #
US - Stati Uniti d'America 25.068
IT - Italia 6.778
UA - Ucraina 2.279
TR - Turchia 1.607
SE - Svezia 1.186
IE - Irlanda 797
DE - Germania 766
VN - Vietnam 731
CN - Cina 594
FI - Finlandia 509
GB - Regno Unito 419
SG - Singapore 297
FR - Francia 194
RU - Federazione Russa 59
IN - India 44
EU - Europa 29
JP - Giappone 27
CA - Canada 24
BE - Belgio 23
NL - Olanda 23
CZ - Repubblica Ceca 17
BR - Brasile 14
CL - Cile 11
ES - Italia 9
PT - Portogallo 8
AU - Australia 7
CH - Svizzera 7
RO - Romania 7
AT - Austria 6
GR - Grecia 6
HK - Hong Kong 5
HU - Ungheria 4
IR - Iran 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
AR - Argentina 3
EG - Egitto 3
ID - Indonesia 3
IL - Israele 3
MY - Malesia 3
NO - Norvegia 3
PK - Pakistan 3
PL - Polonia 3
DK - Danimarca 2
HN - Honduras 2
KR - Corea 2
LI - Liechtenstein 2
RS - Serbia 2
SI - Slovenia 2
TW - Taiwan 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 41.627
Città #
Milan 4.990
Fairfield 4.108
Woodbridge 2.671
Ashburn 2.022
Houston 1.922
Jacksonville 1.808
Seattle 1.604
Wilmington 1.492
Chandler 1.387
Cambridge 1.384
Ann Arbor 1.312
Izmir 813
Dublin 792
Princeton 787
Dearborn 591
Nyköping 539
Boardman 496
Dong Ket 367
Rome 313
Singapore 288
San Diego 243
San Mateo 159
Ogden 152
Beijing 127
Como 126
Chicago 119
Washington 102
London 95
Santa Clara 74
New York 72
Düsseldorf 70
Hefei 62
Redmond 62
Nanjing 59
Los Angeles 58
Helsinki 56
Norwalk 53
Kunming 50
Verona 48
Kocaeli 39
Paris 37
Dallas 31
Kilburn 30
Jinan 29
Munich 25
Nanchang 24
Frankfurt am Main 23
Tokyo 22
Besana In Brianza 20
Falls Church 19
Ponte Lambro 19
Redwood City 19
Brussels 18
Guangzhou 18
Prescot 18
Fuzhou 17
Chiswick 16
Toronto 16
Brno 15
Acton 14
Indiana 14
Shenyang 14
Varese 14
Berlin 13
Philadelphia 13
Bergamo 12
Hounslow 12
Wandsworth 11
Busto Arsizio 10
Hebei 10
New Bedfont 10
San Francisco 10
Southwark 10
Wuhan 10
Xian 10
Changsha 9
Islington 9
Pune 9
Phoenix 8
Ralingen 8
Suresnes 8
São Paulo 8
Zhengzhou 8
Chongqing 7
Magnago 7
Ningbo 7
Torino 7
Abbiategrasso 6
Detroit 6
Genoa 6
Hangzhou 6
Legnano 6
Saint Louis 6
Amsterdam 5
Andover 5
Baotou 5
Brescia 5
Cleveland 5
Lappeenranta 5
Novara 5
Totale 32.281
Nome #
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 226
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 224
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 220
Risk of recurrence of unusual site venous thromboembolism 213
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 203
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis 194
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 194
Optimal treatment duration of venous thrombosis 190
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 189
Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature 189
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 188
Patient selection for thromboprophylaxis in medical inpatients 186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 185
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 183
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 180
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 179
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 179
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 178
Venous ischemic syndromes 178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 176
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 175
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 174
Warfarin interactions with antibiotics in the ambulatory care setting 171
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 171
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 171
Duration of anticoagulation after venous thromboembolism in real world clinical practice 170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 170
Venous and arterial thrombosis in patients with HIV infection 168
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens 168
Seasonal and monthly variation in occurrence of hypertensive urgency 167
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis 166
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation 164
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 163
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 163
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation. 163
Statins and secondary prevention of ischemic and hemorrhagic stroke 162
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature 161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 160
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding 160
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 160
ABO blood group and vascular disease: an update 160
Low-molecular -weight heparin in pregnancies after ART -A retrospective study- 158
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 156
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 156
Is diabetes a hypercoagulable state? A critical appraisal 156
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. 155
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 155
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 155
sRAGE and early signs of cardiac target organ damage in mild hypertensives 155
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs 155
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment 154
Prevention of in-hospital VTE: why can't we do better? 153
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events 153
How I treat splanchnic vein thrombosis 152
The role of thrombolytic therapy in pulmonary embolism 152
Statins for acute ischemic stroke 152
In vitro effects of Apixaban on 5 different cancer cell lines 151
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal 150
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. 150
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. 149
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: Comment 149
In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: A sex effect? 149
The effect of thyroid autoantibodies on warfarin stability 149
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study 148
Italian intersociety consensus on DOAC use in internal medicine 147
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience 146
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 146
Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: Results of a patient-level meta-analysis 146
Direct oral anticoagulants for superficial-vein thrombosis 145
The prevention and treatment of venous thromboembolism in pregnancy 145
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 144
Management of hypertension in overweight and obese patients: a practical guide for clinicians. 144
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening 144
Neutrophil-to-lymphocyte ratio: A new prognostic factor even in patients with heart failure 144
Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study 143
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy 143
Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence 143
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 142
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 142
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. 142
Risk of Thromboembolism, Recurrent Hemorrhage, and Death after Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding 142
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 141
Nonadherence with INR monitoring and anticoagulant complications 141
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism 141
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. 139
Natural anticoagulants deficiency and the risk of venous thromboembolism: A meta-analysis of observational studies 139
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. 138
Statins, fibrates, and venous thromboembolism: a meta-analysis. 137
Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant or antiplatelet drugs 137
The role of the metabolic syndrome in patients with provoked venous thromboembolic events 137
Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry 137
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. 136
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. 136
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients 136
JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease. 135
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 135
Totale 16.090
Categoria #
all - tutte 173.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.816


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.603 0 0 0 1.754 653 965 1.231 1.043 721 571 169 496
2020/20217.056 145 653 766 695 409 732 291 619 838 458 574 876
2021/20224.033 403 544 187 104 219 172 325 215 229 726 411 498
2022/20234.345 480 206 318 379 303 956 14 560 651 238 132 108
2023/20248.113 1.241 1.276 1.284 1.554 1.634 559 57 105 238 74 32 59
2024/20251.293 36 47 1.117 93 0 0 0 0 0 0 0 0
Totale 42.145